OncoTherad® is an immunomodulator of biological response that downregulate RANK/RANKL signaling pathway and PD-1/PD-L1 immune checkpoint in non-muscle invasive bladder cancer

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.contributorUniversidade Estadual Paulista (UNESP)-
Autor(es): dc.contributorUniversidade Estadual de Campinas (UNICAMP)-
Autor(es): dc.contributorUniversidade Federal do ABC (UFABC)-
Autor(es): dc.creatorReis, Ianny Brum-
Autor(es): dc.creatorTibo, Luiz Henrique Soares-
Autor(es): dc.creatorde Souza, Bianca Ribeiro-
Autor(es): dc.creatorDurán, Nelson-
Autor(es): dc.creatorFávaro, Wagner José-
Data de aceite: dc.date.accessioned2025-08-21T23:03:18Z-
Data de disponibilização: dc.date.available2025-08-21T23:03:18Z-
Data de envio: dc.date.issued2023-07-29-
Data de envio: dc.date.issued2023-07-29-
Data de envio: dc.date.issued2021-12-31-
Fonte completa do material: dc.identifierhttp://dx.doi.org/10.1007/s00432-022-04449-5-
Fonte completa do material: dc.identifierhttp://hdl.handle.net/11449/247833-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/11449/247833-
Descrição: dc.descriptionIntoduction: Bladder cancer is the second most common urinary tract cancer. Above 70% of the occurrence of bladder cancer is superficial (pTis, pTa, and pT1), non-muscle invasive tumor (NMIBC), and the incidence of invasive disease is occasional. Treatments for NMIBC consist of transurethral resection (TUR) and subsequently intravesical immunotherapy with Bacillus Calmette-Guérin (BCG), intending to prevent tumor progression and decrease recurrence. However, 20–30% of these tumors have progression, and 70% have a recurrence after exclusive TUR treatment. The immunomodulator of biological response, OncoTherad®, is an attractive potential to revolutionize cancer therapy. In our previous studies with mice, the results showed that treatment with OncoTherad® reduced 100% of tumor progression in NMIBC through the activation of Toll-Like Receptors’ non-canonical pathway. Materials and Methods: In the present study, 36 female C57Bl/6J mice were divided into 6 groups (n = 6/group): Control, Cancer, Cancer + BCG, Cancer + OncoTherad® (MRB-CFI-1), Cancer + P14-16 and Cancer + CFI-1. NMIBC was chemically induced and the treatments were followed for 6 weeks. A week after the last dose of treatment, animals were euthanized, the bladder was collected and routinely processed for immunohistochemical analyses of RANK, RANKL, FOXP3, and PD-1/PD-L1, such as PD-1/PD-L1 western blotting. Conclusion: The immunohistochemical results showed that OncoTherad® reduced RANK and RANKL immunoreactivities compared to the cancer group, which indicates a good prognosis. Immunohistochemical and western blotting analyses confirmed that OncoTherad® modulated PD-1/PD-L1 immune checkpoint.-
Descrição: dc.descriptionDepartment of Diagnosis and Surgery School of Dentistry at Araraquara São Paulo State University (UNESP), Rua Humaitá, 1680–Centro, SP-
Descrição: dc.descriptionInstitute of Biology Universidade Estadual de Campinas/UNICAMP, SP-
Descrição: dc.descriptionNanomedicine Research Unit (Nanomed) Federal University of ABC (UFABC), SP-
Descrição: dc.descriptionDepartment of Diagnosis and Surgery School of Dentistry at Araraquara São Paulo State University (UNESP), Rua Humaitá, 1680–Centro, SP-
Idioma: dc.languageen-
Relação: dc.relationJournal of Cancer Research and Clinical Oncology-
???dc.source???: dc.sourceScopus-
Palavras-chave: dc.subjectCancer treatment-
Palavras-chave: dc.subjectFOXP3-
Palavras-chave: dc.subjectImmune checkpoint-
Palavras-chave: dc.subjectImmune system-
Palavras-chave: dc.subjectRANKL-
Título: dc.titleOncoTherad® is an immunomodulator of biological response that downregulate RANK/RANKL signaling pathway and PD-1/PD-L1 immune checkpoint in non-muscle invasive bladder cancer-
Tipo de arquivo: dc.typelivro digital-
Aparece nas coleções:Repositório Institucional - Unesp

Não existem arquivos associados a este item.